CYP11B1基因新突变致11β-羟化酶缺陷症1例家系研究

doi:10.6040/j.issn.1671-7554.0.2017.218

摘要/Abstract

摘要： 目的分析1例经典型11β-羟化酶缺乏症患者的临床表现及其家系基因型特点。方法分析2016年3月9日诊断的1例经典型11β-羟化酶缺乏症患者的临床特征、诊疗结果、随访情况及基因测序,并结合文献进行回顾性分析。结果患者,男,29岁,发作性四肢麻痹20余年,当地医院检查发现低钾血症伴高血压,查体示身高155 cm,全身皮肤颜色较黑,自幼较同龄人生长发育迅速,8岁后身高增长不明显。CT示双侧肾上腺占位,实验室检查血浆促肾上腺皮质激素301.70 pg/mL、17-羟孕酮 23.83 ng/mL、血清睾酮997.04 ng/dL、硫酸去氢表雄酮921.70 μg/dL、雄烯二酮>10.30 ng/mL、立位肾素活性1.90 μIU/(mL·h)、醛固酮/肾素活性0.72。使用地塞米松0.75 mg/d(睡前服用)联合复方利血平氨苯喋啶片可有效抑制ACTH、雄激素水平及控制血压。CYP11B1基因分析示患者存在新纯合剪接突变c.595+1G>A,其母亲、姐姐为该突变携带者,生物学父亲未见异常。结论糖皮质激素联合利血平氨苯喋啶片可用于经典型11β-羟化酶患者治疗。基因型c.595+1G>A突变与经典型11β-羟化酶缺陷症有关。

关键词: 11β-羟化酶缺陷症, 基因, 突变, 先天性肾上腺增生, CYP11B1

Abstract: Objective To study the clinical features and the results of CYP11B1 gene analysis of a Chinese adult with classical 11β-hydroxylase deficiency. Methods One case diagnosed with classical 11β-hydroxylase deficiency in our department in 2016 was enrolled in this study. The clinical characteristics, diagnosis, treatment and gene analysis were reported and the related literature was reviewed. Results The male patient, 29 years old, paroxysmal paralysis for more than 20 years with accelerated skeletal maturation, resultant short stature and peripheral precocious puberty. CT showed bilateral adrenal occupying lesions. Laboratory examinations found plasma ACTH 301.70 pg/mL,serum 17α-hydoxy progesterone 23.83 ng/mL, testosterone 997.04 ng/dL, dehydroepiandrosterone sulfate 921.70 g/dL, androstenedione >10.30 ng/mL, orthostatic renin activity 1.90 μIU/(mL·h), aldosterone / renin activity 0.72. Dexamethasone 0.75 mg/d(bedtime)combined with compound reserpine triamterene tablets was given to the patient which effectively inhibit ACTH and androgen levels and blood pressure. A novel splicing mutation c.595+1G>A was identified in CYP11B1 gene of the patient. The mutation of the patient was homozygous and his mother and sister was heterozygous, while his father was not identified with this mutation. Conclusion Glucocorticoid combined with reserpine triamterene tablets can be used in the classical 11β-hydroxylase deficiency. A novel homozygous mutation c.595+1G>A was related to the classical phenotype.

Key words: Mutation, Congenital adrenal hyperplasia, 11β-hydroxylase deficiency, CYP11B1, Gene

中图分类号:

R586.9

刘贺,刘福强,侯新国,陈丽. CYP11B1基因新突变致11β-羟化酶缺陷症1例家系研究[J]. 山东大学学报（医学版）, 2017, 55(9): 85-89.

LIU He, LIU Fuqiang, HOU Xinguo, CHEN Li. A study of 11β-hydroxylase defect induced by a novel CYP11B1 gene mutation in one family[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 85-89.

参考文献

[1] Polat S, Kulle A, Karaca Z, et al. Characterisation of three novel CYP11B1 mutations in classic and non-classic 11beta-hydroxylase deficiency[J]. Eur J Endocrinol, 2014, 170(5): 697-706.
[2] Menabo S, Polat S, Baldazzi L, et al. Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency: functional consequences of four CYP11B1 mutations[J]. Eur J Hum Genet, 2014, 22(5): 610-616.
[3] 许岭翎, 陆召麟, 戴为信,等. 11β- 羟化酶缺陷症 9例临床特征与治疗分析[J]. 中国实用内科杂志, 2007, 27(7): 519-522. XU Lingling, LU Zhaolin, DAI Weixin, et al. Clinical characteristics and treatment of 11 beta-hydroxylase deficiency - report of 9 cases and literature review[J]. Chinese Journal of Practical Internal Medicine, 2007, 27(7): 519-522.
[4] Speiser PW, White PC. Congenital adrenal hyperplasia[J]. N Engl J Med, 2003, 349(8): 776-788.
[5] Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients[J]. J Clin Endocrinol Metab, 1983, 56(2): 222-229.
[6] Ben Charfeddine I, Riepe FG, Kahloul N, et al. Two novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11beta hydroxylase deficiency in a Tunisian family[J]. Gen Comp Endocrinol, 2012, 175(3): 514-518.
[7] Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency[J]. Endocrine, 2017, 55(1): 19-36.
[8] Wang X, Nie M, Lu L, et al. Identification of seven novel CYP11B1 gene mutations in Chinese patients with 11 beta-hydroxylase deficiency[J]. Steroids, 2015, 100: 11-16. doi: 10.1016/j.steroids.2015.04.003.
[9] Desviat LR, Perez B, Ugarte M. Minigenes to confirm exon skipping mutations[J]. Methods Mol Biol, 2012, 867: 37-47. doi: 10.1007/978-1-61779-767-5_3.
[10] Nguyen HH, Eiden-Plach A, Hannemann F, et al. Phenotypic, metabolic, and molecular genetic characterization of six patients with congenital adrenal hyperplasia caused by novel mutations in the CYP11B1 gene[J]. J Steroid Biochem Mol Biol, 2016, 155(Part A): 126-134.
[11] Matsubara K, Kataoka N, Ogita S, et al. Uniparental disomy of chromosome 8 leading to homozygosity of a CYP11B1 mutation in a patient with congenital adrenal hyperplasia: implication for a rare etiology of an autosomal recessive disorder[J]. Endocr J, 2014, 61(6): 629-633.
[12] Yamazawa K, Ogata T, Ferguson-Smith AC. Uniparental disomy and human disease: an overview[J]. Am J Med Genet C Semin Med Genet, 2010, 154C(3): 329-334.
[13] 孙首悦,杨曼娜,杨军,等. 11β-羟化酶缺陷症临床和基因型分析[J]. 中华医学杂志, 2011, 91(42): 2999-3002. SUN Shouyue, YANG Manna, YANG Jun, et al. Clinical and genetic analysis of 11β-hydroxylase deficiency[J]. Natl Med J China, 2011, 91(42): 2999-3002.
[14] Kaynar M, Sonmez MG, Unlu Y, et al. Testicular adrenal rest tumor in 11-Beta-hydroxylase deficiency driven congenital adrenal hyperplasia[J]. Korean J Urol, 2014, 55(4): 292-294.
[15] Han TS, Walker BR, Arlt W, et al. Treatment and health outcomes in adults with congenital adrenal hyperplasia[J]. Nat Rev Endocrinol, 2014, 10(2): 115-124.
[16] 刘小荣,张笠,王勇平,等. 实时荧光定量PCR技术的理论研究及其医学应用[J]. 中国组织工程研究与临床, 2010, 14(2): 329-332. LIU Xiaorong, ZHANG Li, WANG Yongping, et al. Theory study and medical application of real-time quantitative polymerase chain reaction[J]. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(2): 329-332.

相关文章 15

[1]	张士宝刘庆勇阮喜云陈杰张建军李宗武杨广笑王全颖. NT₄-SAC-HA₂-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[2]	葛丽娟金瑞峰王纪文许新升李癊. 多药耐药基因1 C1236T多态性与癫痫患者对药物反应性的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 99-102.
[3]	郝跃伟刘雪平赵婷婷郑敏王一兵. 环氧化酶2基因多态性与动脉粥样硬化缺血性脑卒中的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 95-98.
[4]	胡思翠,孙清,王一冰,孙莉莉,隋炎希,李堂. Bartter综合征二例家系报告与CLCNKB基因突变分析[J]. 山东大学学报 (医学版), 2020, 1(9): 64-70.
[5]	吴强,何泽鲲,刘琚,崔晓萌,孙双,石伟. 基于机器学习的脑胶质瘤多模态影像分析[J]. 山东大学学报 (医学版), 2020, 1(8): 81-87.
[6]	焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.
[7]	宋立,张艳,刘洋,王丹. 随访2年观察1例新发突变的营养不良型大疱性表皮松解症[J]. 山东大学学报 (医学版), 2020, 1(8): 120-122.
[8]	付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[9]	徐继禧,陈伟健. 髓内弥漫性中线胶质瘤伴H3 K27M突变1例[J]. 山东大学学报 (医学版), 2020, 1(7): 96-101.
[10]	殷雷,殷睿,李文佳,刘帅,吕家驹. CYLD抑制自噬提高膀胱癌细胞吉西他滨化疗敏感性[J]. 山东大学学报（医学版）, 2017, 55(8): 1-6.
[11]	张新科,陈洪元,杨莹,李妍,王凤山. 载pVAX1/Tat PTD-endostatin壳聚糖纳米基因载体的构建与体外活性评价[J]. 山东大学学报（医学版）, 2017, 55(7): 43-48.
[12]	李雁翔,张温花,杨飞龙,方量,徐忠华. 尿路上皮癌BRCA1基因与蛋白表达的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 91-94.
[13]	杜金阁,陈慧,杨孝荣,吕明. STAT4 rs7574865位点单核苷酸多态性与系统性红斑狼疮易感性Meta分析[J]. 山东大学学报（医学版）, 2017, 55(5): 95-102.
[14]	李雪,李栋,时庆,周盼盼,鞠秀丽. Helios在儿童急性淋巴细胞性白血病调节性T细胞中的表达及功能[J]. 山东大学学报（医学版）, 2017, 55(4): 76-81.
[15]	唐小敏,张丽,叶绪芳,任刚,左丽. 贵州省2013年麻疹病毒核蛋白基因特征分析[J]. 山东大学学报（医学版）, 2017, 55(3): 70-74.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed